Characterisation of a novel NR4A2 mutation in Parkinson's disease brain

Neuroscience Letters

Volumn 457, Issue 2, 2009, Pages 75-79

  Sleiman, P M A ^a   Healy, D G ^a   Muqit, M M K ^a,b   Yang, Y X ^b   Van Der Brug, M ^c   Holton, J L ^a   Revesz, T ^a   Quinn, N P ^a   Bhatia, K ^a   Diss, J K J ^b   Lees, A J ^a,d   Cookson, M R ^c   Latchman, D S ^b,e   Wood, N W ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c NATIONAL INSTITUTE ON AGING   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Allele specific expression analysis; NR4A2; Parkinsonism; Whole genome expression analysis

Indexed keywords

MESSENGER RNA;

5' UNTRANSLATED REGION; ALLELE; APOPTOSIS; ARTICLE; BRAIN TISSUE; CELL PROTECTION; CELL STRESS; CONTROLLED STUDY; DOWN REGULATION; GENE; GENE EXPRESSION; GENE MUTATION; GENOME ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MORPHOGENESIS; MUTATIONAL ANALYSIS; NERVE CELL; NERVOUS SYSTEM DEVELOPMENT; NR4A2 GENE; NUCLEIC ACID BASE SUBSTITUTION; PARKINSON DISEASE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SYNAPTIC TRANSMISSION; WILD TYPE;

BRAIN; CELL LINE; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; NEURONS; PARKINSON DISEASE; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS;

EID: 67349149636     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2009.03.021     Document Type: Article

References (25)

1. Abou-Sleiman P.M., Muqit M.M., and Wood N.W. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat. Rev. Neurosci. 7 (2006) 207-219
2. Baptista M.J., O'Farrell C., Daya S., Ahmad R., Miller D.W., Hardy J., Farrer M.J., and Cookson M.R. Co-ordinate transcriptional regulation of dopamine synthesis genes by alpha-synuclein in human neuroblastoma cell lines. J. Neurochem. 85 (2003) 957-968
3. Diss J.K., Stewart D., Pani F., Foster C.S., Walker M.M., Patel A., and Djamgoz M.B. A potential novel marker for human prostate cancer: voltage-gated sodium channel expression in vivo. Prostate Cancer Prostatic Dis. 8 (2005) 266-273
4. Eells J.B., Lipska B.K., Yeung S.K., Misler J.A., and Nikodem V.M. Nurr1-null heterozygous mice have reduced mesolimbic and mesocortical dopamine levels and increased stress-induced locomotor activity. Behav. Brain Res. 136 (2002) 267-275
5. Falcon S.G. Using GOstats to test gene lists for GO term association. Bioinformatics 23 (2007) 257-258
6. Farrer M.J. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat. Rev. Genet. 7 (2006) 306-318
7. Gibb W.R.L., and Lees A.J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 51 (1988) 745-752
8. Grimes D.A., Han F., Panisset M., Racacho L., Xiao F., Zou R., Westaff K., and Bulman D.E. Translated mutation in the Nurr1 gene as a cause for Parkinson's disease. Mov. Disord. 21 (2006) 906-909
9. Hering R., Petrovic S., Mietz E.M., Holzmann C., Berg D., Bauer P., Woitalla D., Muller T., Berger K., Kruger R., and Riess O. Extended mutation analysis and association studies of Nurr1 (NR4A2) in Parkinson disease. Neurology 62 (2004) 1231-1232
10. Ibanez P., Lohmann E., Pollak P., Durif F., Tranchant C., Agid Y., Durr A., and Brice A. Absence of NR4A2 exon 1 mutations in 108 families with autosomal dominant Parkinson disease. Neurology 62 (2004) 2133-2134
11. Jiang C., Wan X., He Y., Pan T., Jankovic J., and Le W. Age-dependent dopaminergic dysfunction in Nurr1 knockout mice. Exp. Neurol. 191 (2005) 154-162
12. Karamohamed S., Golbe L.I., Mark M.H., Lazzarini A.M., Suchowersky O., Labelle N., Guttman M., Currie L.J., Wooten G.F., Stacy M., Saint-Hilaire M., Feldman R.G., Liu J., Shoemaker C.M., Wilk J.B., DeStefano A.L., Latourelle J.C., and Xu G. Absence of previously reported variants in the SCNA (G88C and G209A), NR4A2 (T291D and T245G) and the DJ-1 (T497C) genes in familial Parkinson's disease from the GenePD study. Mov. Disord. 20 (2005) 1188-1191
13. Law S.W., Conneely O.M., DeMayo F.J., and O'Malley B.W. Identification of a new brain-specific transcription factor, NURR1. Mol. Endocrinol. 6 (1992) 2129-2135
14. Le W., Conneely O.M., He Y., Jankovic J., and Appel S.H. Reduced Nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-induced injury. J. Neurochem. 73 (1999) 2218-2221
15. Le W.D., Xu P., Jankovic J., Jiang H., Appel S.H., Smith R.G., and Vassilatis D.K. Mutations in NR4A2 associated with familial Parkinson disease. Nat. Genet. 33 (2003) 85-89
16. Levecque C., Destee A., Mouroux V., Amouyel P., and Chartier-Harlin M.C. Assessment of Nurr1 nucleotide variations in familial Parkinson's disease. Neurosci. Lett. 366 (2004) 135-138
17. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25 (2001) 402-408
18. Qiu J.H., Asai A., Chi S., Saito N., Hamada H., and Kirino T. Proteasome inhibitors induce cytochrome c-caspase-3-like protease-mediated apoptosis in cultured cortical neurons. J. Neurosci. 20 (2000) 259-265
19. Sacchetti P., Mitchell T.R., Granneman J.G., and Bannon M.J. Nurr1 enhances transcription of the human dopamine transporter gene through a novel mechanism. J. Neurochem. 76 (2001) 1565-1572
20. Sakurada K., Ohshima-Sakurada M., Palmer T.D., and Gage F.H. Nurr1, an orphan nuclear receptor, is a transcriptional activator of endogenous tyrosine hydroxylase in neural progenitor cells derived from the adult brain. Development 126 (1999) 4017-4026
21. Suzuki R., and Shimodaira H. Pvclust: an R package for assessing the uncertainty in hierarchical clustering. Bioinformatics 22 (2006) 1540-1542
22. Tan E.K., Chung H., and Chandran V.R. V.R. Nurr1 mutational screen in Parkinson's disease. Mov. Disord. 19 (2004) 1503-1505
23. Wellenbrock C., Hedrich K., Schafer N., Kasten M., Jacobs H., Schwinger E., Hagenah J., Pramstaller P.P., Vieregge P., and Klein C. NR4A2 mutations are rare among European patients with familial Parkinson's disease. Ann. Neurol. 54 (2003) 415
24. Zetterstrom R.H., Solomin L., Jansson L., Hoffer B.J., Olson L., and Perlmann T. Dopamine neuron agenesis in Nurr1-deficient mice. Science 276 (1997) 248-250
25. Zimprich A., Asmus F., Leitner P., Castro M., Bereznai B., Homann N., Ott E., Rutgers A.W., Wieditz G., Trenkwalder C., and Gasser T. Point mutations in exon 1 of the NR4A2 gene are not a major cause of familial Parkinson's disease. Neurogenetics 4 (2003) 219-220